Andrew Gerry spricht Montag/Dienstag in London..
http://www.tcellsummit.com/speakers.htmlAndrew Gerry - Director of Preclinical Research - Adaptimmune
Dr Andrew Gerry (Jez) leads the Cell Pipeline and Preclinical group including Molecular safety characterisation and cell screening within Adaptimmune. He obtained his PhD from University of Reading in Cell and Molecular Biology in 2004, and held a postdoctoral position investigating the role of macrophages in atherosclerosis. He joined Medigene Ltd in 2007 and subsequently set up the Cell Biology Group at Adaptimmune Ltd in 2008.
Jez led the preclinical safety and potency testing of Adaptimmune’s lead programme, NYESOc259 TCR, which has been showing promising data in clinical trials in multiple myeloma and synovial sarcoma. More recently, Jez led the preclinical phase of MAGE-A10c796 development which is now recruiting patients with non-small cell lung carcinoma.
Investigations into the cause of cardiac toxicity seen in their MAGE-A3a3a TCR programs led to the identification of cross-reactivity to a peptide derived from the contractile protein Titin, and the subsequent development of Adaptimmune’s current extensive in vitro preclinical safety screening process for new enhanced-affinity TCRs.
Within Jez’ current role as Director of Preclinical Research at Adaptimmune, he leads a team that evaluate new TCRs for potency and specificity, the selection of optimally-engineered TCRs and the extensive evaluation of specificity and safety of new optimal TCRs for adoptive T cell therapy.